iPSC Services

iPS Cell Generation

iPSC services: Induced Pluripotent stem cells (iPSCs) are a type of pluripotent stem cells that can be reprogrammed from adult somatic cells, derived from healthy or diseased patients. These pluripotent stem cells provide a limitless supply of patient-derived samples to develop in vitro preclinical models of diseases, that represent the genetic and epigenetic features of a disease better. As well, iPSCs are amenable to genome editing which has been a stumbling block for developing research models using primary cells lines.

Applied StemCell (ASC) provides a wide range of integrated embryonic stem cell (ESC) and iPSC services, including iPSC generation/ ESC derivation, disease modeling/ correction using CRISPR/Cas9 and our proprietary TARGATT™ genome editing technologies, a complete panel of stem cell characterization (teratoma formation assays, pluripotency marker assays and more), and stem cell differentiation.

ASC is one of the earliest licensees of both the iPSC reprogramming factors from iPS Academia, Japan and the CRISPR/Cas9 technology from the Broad Institute. Using optimized, feeder-free protocols, we are experts in handling and maintaining healthy, pluripotent iPSCs at every stage of your project(s). ASC’s acclaimed CRISPR/Cas9 modified iPSC services for in vitro genetic disease modeling has even been featured in the article, “CRISPR/Cas9-transforming gene editing in drug discovery labs” (Comley, et al., 2016) published by the peer-reviewed magazine, Drug Discovery Weekly. 

As experts in both stem cell technology and CRISPR genome editing, we have a unique place in the genome editing marketplace which researchers can leverage to their advantage. We also provide fully customizable deliverables for our customers and a one-stop solution to meet all iPSC needs with our affordable and comprehensive portfolio of iPSC services, dedicated project managers, detailed high quality reports and a seamless workflow.